ASX:CSLBiotechs
CSL (ASX:CSL) Valuation Check After Robust Five-Year HEMGENIX Gene Therapy Results
CSL (ASX:CSL) has sparked fresh interest after unveiling five year HOPE B trial results for its gene therapy HEMGENIX, showing sustained efficacy and safety that could reshape reimbursement debates, especially in Australia.
See our latest analysis for CSL.
Yet despite a string of positives, from the new Melbourne vaccine facility to the ongoing buy-back and now the standout HEMGENIX data, CSL’s 1 year total shareholder return of around minus 34 percent and steep year to date share price...